Cover Image
市場調查報告書

移植物抗宿主病 (GVHD):開發中產品分析

Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 234335
出版日期 內容資訊 英文 417 Pages
訂單完成後即時交付
價格
Back to Top
移植物抗宿主病 (GVHD):開發中產品分析 Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2017
出版日期: 2017年09月19日 內容資訊: 英文 417 Pages
簡介

移植物抗宿主病 (GVHD),是移植幹細胞或骨髓移植,捐贈者的新的細胞攻擊移植患者的身體發生的併發症。症狀有腹痛或激烈的腹痛,噁心,嘔吐,腹瀉,眼睛乾燥閃疼,黃疸,呼吸急促,陰道乾燥及體重降低等。治療為使用免疫抑制劑。

本報告提供移植物抗宿主病 (GVHD)的治療方法的相關市場相關分析,治療藥的開發、臨床實驗的最新趨勢,及相關企業、組織簡介,開發中的產品,產業的最新趨勢的資訊彙整。

簡介

  • 調查範圍

移植物抗宿主病 (GVHD)的概要

治療藥的開發

移植物抗宿主病 (GVHD):治療藥的評估

移植物抗宿主病 (GVHD)的開發治療藥的企業

藥物簡介

移植物抗宿主病 (GVHD):暫停中的計劃

移植物抗宿主病 (GVHD):開發中止的產品

移植物抗宿主病 (GVHD):產品開發里程碑

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9732IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2017, provides an overview of the Graft Versus Host Disease (GVHD) (Immunology) pipeline landscape.

Graft-versus-host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted donor cells attack the transplant recipient's body. Symptoms include abdominal pain or cramps, nausea, vomiting, and diarrhea, dry or irritated eyes, jaundice, shortness of breath, vaginal dryness and weight loss. Treatment includes immunosuppressants.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Graft Versus Host Disease (GVHD) (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Graft Versus Host Disease (GVHD) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Graft Versus Host Disease (GVHD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 7, 23, 9, 44, 9 and 2 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 1, 3, 13 and 2 molecules, respectively.

Graft Versus Host Disease (GVHD) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Graft Versus Host Disease (GVHD) (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Graft Versus Host Disease (GVHD) (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Graft Versus Host Disease (GVHD) (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Graft Versus Host Disease (GVHD) (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Graft Versus Host Disease (GVHD) (Immunology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Graft Versus Host Disease (GVHD) (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Graft Versus Host Disease (GVHD) (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Graft Versus Host Disease (GVHD) - Overview
  • Graft Versus Host Disease (GVHD) - Therapeutics Development
  • Graft Versus Host Disease (GVHD) - Therapeutics Assessment
  • Graft Versus Host Disease (GVHD) - Companies Involved in Therapeutics Development
  • Graft Versus Host Disease (GVHD) - Drug Profiles
  • Graft Versus Host Disease (GVHD) - Dormant Projects
  • Graft Versus Host Disease (GVHD) - Discontinued Products
  • Graft Versus Host Disease (GVHD) - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Graft Versus Host Disease (GVHD), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..4), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by AbbVie Inc, H2 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by AbGenomics International Inc, H2 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Allergan Plc, H2 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Amunix Operating Inc, H2 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by AnaptysBio Inc, H2 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by apceth Biopharma GmbH, H2 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Aptevo Therapeutics Inc, H2 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by arGEN-X BV, H2 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Athersys Inc, H2 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Bellicum Pharmaceuticals Inc, H2 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Bio-Cancer Treatment International Ltd, H2 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Biogen Inc, H2 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Bristol-Myers Squibb Company, H2 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Capricor Therapeutics Inc, H2 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Cell2B Advanced Therapeutics SA, H2 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Cellect Biomed Ltd, H2 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Commence Bio Inc, H2 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Cynata Therapeutics Ltd, H2 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Cytodyn Inc, H2 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Escape Therapeutics Inc, H2 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Fate Therapeutics Inc, H2 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Generon (Shanghai) Corp Ltd, H2 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Gilead Sciences Inc, H2 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by GlaxoSmithKline Plc, H2 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Incyte Corp, H2 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Jazz Pharmaceuticals Plc, H2 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Johnson & Johnson, H2 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Kadmon Corp LLC, H2 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Kamada Ltd, H2 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Kiadis Pharma NV, H2 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Kymab Ltd, H2 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by MacroGenics Inc, H2 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Mallinckrodt Plc, H2 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Mesoblast Ltd, H2 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Millennium Pharmaceuticals Inc, H2 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Nohla Therapeutics Inc, H2 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Novartis AG, H2 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by OncoImmune Inc, H2 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Pfizer Inc, H2 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Pharmicell Co Ltd, H2 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by REGiMMUNE Corp, H2 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Sanofi, H2 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Sarepta Therapeutics Inc, H2 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Seattle Genetics Inc, H2 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Seres Therapeutics Inc, H2 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Sigmoid Pharma Ltd, H2 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Synedgen Inc, H2 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Targazyme Inc, H2 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by TC BioPharm Ltd, H2 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by TxCell SA, H2 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by United BioPharma Inc, H2 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Vault Pharma Inc, H2 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by VBI Vaccines Inc, H2 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Xenikos BV, H2 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by XL-protein GmbH, H2 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by ZIOPHARM Oncology Inc, H2 2017
  • Graft Versus Host Disease (GVHD) - Dormant Projects, H2 2017
  • Graft Versus Host Disease (GVHD) - Dormant Projects, H2 2017 (Contd..1), H2 2017
  • Graft Versus Host Disease (GVHD) - Dormant Projects, H2 2017 (Contd..2), H2 2017
  • Graft Versus Host Disease (GVHD) - Dormant Projects, H2 2017 (Contd..3), H2 2017
  • Graft Versus Host Disease (GVHD) - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Graft Versus Host Disease (GVHD), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Top 10 Molecule Types, H2 2017
  • Number of Products by Stage and Top 10 Molecule Types, H2 2017
Back to Top